August 2023 in “Journal of inflammation research” This case report observed alopecia universalis, a complete hair loss condition, in a patient during a clinical trial with the angiotensin receptor-neprilysin inhibitor sacubitril/alisartan, indicating that ARNI therapy might be associated with such cutaneous reactions.
May 2024 in “International journal of medicine and psychology.” This article describes an increase in the detection of heart failure among young people and discusses the development of the drug Uperio for its treatment and support.
February 2026 in “Oncology Reviews” This review highlights the promising clinical outcomes of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate for breast cancer that targets TROP2, demonstrating improved response rates and progression-free survival, with manageable safety concerns including primarily mild-to-moderate nausea and alopecia.